In a double-blind, placebo-controlled Phase II study, anti-IL-6 monoclonal antibody (siltuximab) was assessed in patients with low- and intermediate-1-risk MDS who require regularly transfusions for MDS anemia. This evidence concerns the gene IL6 and myelodysplastic syndrome.